INBRX-109 in Ewing Sarcoma and Gastrointestinal Stromal Tumor (GIST)
Contact
Description
This study involves taking a study drug called INBRX-109. The overall goal of the study is to find out how safe and effective the study drug is in treating people that have been diagnosed with advanced or metastatic Ewing sarcoma or SDH-deficient solid tumor/Gastrointestinal Stromal Tumor (GIST).
Eligibility and criteria
IRB Number:
23-021736
Eligible age range:
Clinical trial phase:
Phase I
Official title:
What to expect
The study will enroll patients between 12 and 29 years of age that have been diagnosed with an advanced or metastatic Ewing sarcoma or SDH-deficient solid tumor/Gastrointestinal Stromal Tumor (GIST). As a participant in this research, you will:
- Receive a study drug called INBRX-109
- Have research blood tests
- Submit tissue samples from past tumor biopsies
- Have extra or leftover tissue collected if you have a biopsy as a part of your regular cancer care
Related specialties
Related conditions
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.